Post by regenold

2,117 followers

๐—ช๐—ฒโ€™๐—ฟ๐—ฒ ๐—ฝ๐—น๐—ฒ๐—ฎ๐˜€๐—ฒ๐—ฑ ๐˜๐—ผ ๐˜€๐—ต๐—ฎ๐—ฟ๐—ฒ ๐—ฎ๐—ป ๐—ถ๐—บ๐—ฝ๐—ผ๐—ฟ๐˜๐—ฎ๐—ป๐˜ ๐—บ๐—ถ๐—น๐—ฒ๐˜€๐˜๐—ผ๐—ป๐—ฒ ๐—ณ๐—ผ๐—ฟ ๐—ฟ๐—ฒ๐—ด๐—ฒ๐—ป๐—ผ๐—น๐—ฑ. ๐—™๐—ฟ๐—ผ๐—บ ๐˜๐—ผ๐—ฑ๐—ฎ๐˜†, ๐—๐—ฒ๐—ป๐˜€๐—ผ๐—ป๐—ฅ+ ๐˜„๐—ถ๐—น๐—น ๐—ฏ๐—ฒ๐—ฐ๐—ผ๐—บ๐—ฒ ๐—ฟ๐—ฒ๐—ด๐—ฒ๐—ป๐—ผ๐—น๐—ฑ ๐—จ๐—ป๐—ถ๐˜๐—ฒ๐—ฑ ๐—ž๐—ถ๐—ป๐—ด๐—ฑ๐—ผ๐—บ & ๐—œ๐—ฟ๐—ฒ๐—น๐—ฎ๐—ป๐—ฑ, ๐—ฎ๐—ป๐—ฑ ๐—ฃ๐—ง๐—ฅ ๐—ฃ๐—ต๐—ฎ๐—ฟ๐—บ๐—ฎ ๐—–๐—ผ๐—ป๐˜€๐˜‚๐—น๐˜๐—ถ๐—ป๐—ด ๐˜„๐—ถ๐—น๐—น ๐—ฏ๐—ฒ๐—ฐ๐—ผ๐—บ๐—ฒ ๐—ฟ๐—ฒ๐—ด๐—ฒ๐—ป๐—ผ๐—น๐—ฑ ๐—ฃ๐—ผ๐—ฟ๐˜๐˜‚๐—ด๐—ฎ๐—น, ๐˜€๐˜๐—ฟ๐—ฒ๐—ป๐—ด๐˜๐—ต๐—ฒ๐—ป๐—ถ๐—ป๐—ด ๐—ผ๐˜‚๐—ฟ ๐—ฝ๐—ฟ๐—ฒ๐˜€๐—ฒ๐—ป๐—ฐ๐—ฒ ๐—ฎ๐—ป๐—ฑ ๐—ถ๐—ฑ๐—ฒ๐—ป๐˜๐—ถ๐˜๐˜† ๐—ฎ๐—ฐ๐—ฟ๐—ผ๐˜€๐˜€ ๐—ธ๐—ฒ๐˜† ๐—ฟ๐—ฒ๐—ด๐—ถ๐—ผ๐—ป๐˜€. Both organisations have been integral parts of regenold for several years. These transitions reflect how we already operate today, as one connected, global team supporting life sciences companies across every stage of development and commercialisation. Across regenold, we bring together expertise in regulatory, CMC, pre-clinical, clinical, safety, quality and market access, helping our clients navigate complexity and bring products to market worldwide. Our teams in the UK, Ireland and Portugal play a vital role in this, working seamlessly with colleagues and partners across Europe and beyond. This marks an exciting step as we continue to grow as a unified organisation, strengthening collaboration across regions and expanding the support we provide to our clients. Explore our brand new website:ย www.regenold.com

Post content